New York, Jan 14, 2026, 12:49 ET — Regular session
- TMO shares climbed midday after CEO Marc Casper highlighted new contracts tied to U.S. onshoring efforts
- Investors are digesting Thermo’s fresh partnership with Nvidia on lab automation alongside a recent leadership shake-up
- Attention shifts to the January 29 results and the outlook for 2026
Shares of Thermo Fisher Scientific (NYSE: TMO) climbed 1.4% to $615.46 Wednesday after CEO Marc Casper announced that the company’s pharma services division secured contracts linked to “reshoring” — shifting drug manufacturing back from Europe and Asia to the U.S. Speaking at the J.P. Morgan Healthcare Conference, Casper highlighted “a very big focus on reshoring” and noted that a delayed proposed 100% tariff on imported medicines has already prompted customers to accelerate projects and reconsider pricing. Evercore ISI analyst Vijay Kumar described the outlook as “constructive.” Casper also referenced Thermo’s acquisition of Sanofi’s Ridgefield, New Jersey facility last year as a capacity boost and mentioned improving biotech funding. (Reuters)
The remarks came as investors look for clearer demand cues in life-science tools, a sector where orders typically track biotech fundraising rounds and big pharma budget timetables.
For Thermo, this is significant since its contract drug manufacturing and services division operates near those decision points. Setting up or relocating production takes time, yet once underway, it tends to be a long-term commitment.
The stock closed Tuesday down 1.36% at $607.08, trailing a slightly weaker S&P 500, according to MarketWatch. Trading volume hit about 2.8 million shares, well above the 50-day average of roughly 1.7 million. Tuesday’s finish was still 3.34% below the 52-week peak of $628.08 reached on Jan. 6, the report noted. (MarketWatch)
Wednesday saw a mixed bag among peers. Danaher inched up 0.3%, Agilent dipped 0.1%, while Illumina dropped sharply by 4.4%.
Thermo revealed on Monday a new strategic partnership with Nvidia aimed at integrating artificial intelligence into lab instruments and workflows to boost automation. “Artificial intelligence coupled with laboratory automation will transform how scientific work is performed,” said Gianluca Pettiti, an executive vice president at Thermo. (Thermofisher)
Nvidia described the move as closing the gap between lab experiments and machine-learning models, adding it’s also teaming up with Eli Lilly to launch an AI co-innovation lab. “Biology and drug discovery are reaching their transformer moments,” said Kimberly Powell, Nvidia’s vice president of healthcare. (NVIDIA Investor Relations)
A filing on Monday revealed that Thermo’s chief operating officer, Michel Lagarde, is set to leave on March 31, with executive vice president Frederick Lowery departing a month earlier on Feb. 28. Pettiti will step into the role of president and COO starting March 1, and Casper will take on the chairman and CEO positions.
The policy landscape remains uncertain. Tariffs might shift, and moving drug production isn’t quick; if clients hold off on projects, the services growth Casper anticipates in 2027-28 could be delayed or diminished.
Thermo is gearing up to release its fourth-quarter and full-year 2025 earnings before the market opens on Jan. 29, followed by a conference call at 8:30 a.m. ET. Investors will zero in on the 2026 outlook and any updates on its pharma services pipeline, as well as the pace at which Nvidia-related automation projects are translating into orders. (Thermofisher)
